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Abstract 
The research based pharmaceutical industry, with the support of the World Trade Organization's 
Agreement on Trade-Related Aspects on Intellectual Property Rights (TRIPS) has secured its longterm 
profitability. Using an economic rationalist argument of recovering research and development costs, 
pharmaceutical industry representatives have successfully argued for greater patent protection. This 
paper seeks to demonstrate how a powerful cartel of major global pharmaceutical companies through 
multilateral agreements and economic mechanisms protect their 'bottom lines'. The commodification of 
research and development resulting in the private ownership of intellectual property serves to transfer the 
responsibility for the health agenda to the market. This limits the ability of governments, particularly in 
least-developed countries, to address their individual public health issues. By ameliorating the business 
risk presented by countries producing or importing generic medicines, the TRIPS Agreement has 
effectively rendered national health issues subservient to corporate profitability. 
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